ERAS - FDA grants orphan drug status to Erasca brain cancer drug ERAS-801
2023-06-22 17:53:09 ET
The US Food and Drug Administration has granted orphan drug status to Erasca's ( NASDAQ: ERAS ) drug candidate ERAS-801 for the treatment of malignant brain tumors, including glioblastoma.
Erasca said the designation could entitle ERAS-801 to seven years of market exclusivity if it receives FDA approval. The drug received fast track status in April.
ERAS-801 is currently in Phase 1 testing as a monotherapy in patients with recurrent glioblastoma. Initial data from the study is expected during the second half of 2023.
More on Erasca:
- Erasca announces key promotions
- Erasca gains on FDA fast track status for brain cancer therapy
- Erasca: A Pivotal Trial Will Help Make It Stand Out
For further details see:
FDA grants orphan drug status to Erasca brain cancer drug ERAS-801